These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Lipid nanoparticles with different oil/fatty ester ratios as carriers of buprenorphine and its prodrugs for injection. Wang JJ; Liu KS; Sung KC; Tsai CY; Fang JY Eur J Pharm Sci; 2009 Sep; 38(2):138-46. PubMed ID: 19591929 [TBL] [Abstract][Full Text] [Related]
30. Preparation and characteristics of oridonin-loaded nanostructured lipid carriers as a controlled-release delivery system. Dai W; Zhang D; Duan C; Jia L; Wang Y; Feng F; Zhang Q J Microencapsul; 2010 May; 27(3):234-41. PubMed ID: 20113167 [TBL] [Abstract][Full Text] [Related]
31. Preparation and characterization of modified lipid nanoparticles for doxorubicin controlled release. Ying XY; Du YZ; Chen WW; Yuan H; Hu FQ Pharmazie; 2008 Dec; 63(12):878-82. PubMed ID: 19177903 [TBL] [Abstract][Full Text] [Related]
32. Stability of lipid excipients in solid lipid nanoparticles. Radomska-Soukharev A Adv Drug Deliv Rev; 2007 Jul; 59(6):411-8. PubMed ID: 17553589 [TBL] [Abstract][Full Text] [Related]
33. Lipid nanocarriers for dermal delivery of lutein: preparation, characterization, stability and performance. Mitri K; Shegokar R; Gohla S; Anselmi C; Müller RH Int J Pharm; 2011 Jul; 414(1-2):267-75. PubMed ID: 21596122 [TBL] [Abstract][Full Text] [Related]
34. A novel method to produce solid lipid nanoparticles using n-butanol as an additional co-surfactant according to the o/w microemulsion quenching technique. Mojahedian MM; Daneshamouz S; Samani SM; Zargaran A Chem Phys Lipids; 2013 Sep; 174():32-8. PubMed ID: 23743405 [TBL] [Abstract][Full Text] [Related]
35. Preparation and characterization of silybin-loaded nanostructured lipid carriers. Jia LJ; Zhang DR; Li ZY; Feng FF; Wang YC; Dai WT; Duan CX; Zhang Q Drug Deliv; 2010 Jan; 17(1):11-8. PubMed ID: 19941406 [TBL] [Abstract][Full Text] [Related]
36. Preparation, characterization and biodistribution of nanostructured lipid carriers for parenteral delivery of bifendate. Feng F; Zheng D; Zhang D; Duan C; Wang Y; Jia L; Wang F; Liu Y; Gao Q; Zhang Q J Microencapsul; 2011; 28(4):280-5. PubMed ID: 21545318 [TBL] [Abstract][Full Text] [Related]
37. Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems. Uner M Pharmazie; 2006 May; 61(5):375-86. PubMed ID: 16724531 [TBL] [Abstract][Full Text] [Related]
38. Solid lipid nanoparticles for parenteral drug delivery. Wissing SA; Kayser O; Müller RH Adv Drug Deliv Rev; 2004 May; 56(9):1257-72. PubMed ID: 15109768 [TBL] [Abstract][Full Text] [Related]
39. Development of lycopene-loaded nanostructured lipid carriers: effect of rice oil and cholesterol. Riangjanapatee P; Müller RH; Keck CM; Okonogi S Pharmazie; 2013 Sep; 68(9):723-31. PubMed ID: 24147340 [TBL] [Abstract][Full Text] [Related]
40. Optimizing flurbiprofen-loaded NLC by central composite factorial design for ocular delivery. Gonzalez-Mira E; Egea MA; Souto EB; Calpena AC; García ML Nanotechnology; 2011 Jan; 22(4):045101. PubMed ID: 21169662 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]